gut.bmj22h
Contrasting US and European approaches to colorectal cancer screening: which is best?
2 VA Puget Sound Health Care System and Division of Gastroenterology, Department of Medicine, University of Washington, Seattle, Washington, USA In the recent 1–2 decades, we have seen a considerable ...
gut.bmj13d
Microbiota-induced S100A11-RAGE axis underlies immune evasion in right-sided colon adenomas and is a therapeutic target to boost anti-PD1 efficacy
2 Key Laboratory of Human Microbiome and Chronic Diseases (Sun Yat-sen University), Ministry of Education, Guangzhou, China Background Tumourigenesis in right-sided and left-sided colons demonstrated ...
gut.bmj12d
Identification of PRMT5 as a therapeutic target in cholangiocarcinoma
Background Cholangiocarcinoma (CCA) is a very difficult-to-treat cancer. Chemotherapies are little effective and response to immune checkpoint inhibitors is limited. Therefore, new therapeutic ...
gut.bmj11d
Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989
Background and aims RNA interference has been extensively explored in patients with chronic hepatitis B (CHB) infection. We aimed to characterise the long-term efficacy of small interfering RNA (siRNA ...
gut.bmj1d
IDDF2019-ABS-0194 The role of tocotrienols in the treatment of non-alcoholic steatohepatitis- a meta-analysis
Background Chronic liver diseases (CLD) represent a major public health problem, accounting for significant mortality of more than 1.75 million deaths are attributed to it. Among these, Non-alcoholic ...
gut.bmj12d
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic liver disease globally and is currently estimated to affect up to 38% of the global adult population. NAFLD is a ...
gut.bmj10d
Proton pump inhibitors and risk of colorectal cancer
Objective To determine whether proton pump inhibitors (PPIs) are associated with an increased risk of colorectal cancer, compared with histamine-2 receptor antagonists (H2RAs). Design The United ...
gut.bmj9d
Disrupted spermatogenesis in a metabolic syndrome model: the role of vitamin A metabolism in the gut–testis axis
Objective Effects of the diet-induced gut microbiota dysbiosis reach far beyond the gut. We aim to uncover the direct evidence involving the gut–testis axis in the aetiology of impaired ...
gut.bmj10d
Milk polar lipids reduce lipid cardiovascular risk factors in overweight postmenopausal women: towards a gut sphingomyelin-cholesterol interplay
3 Université Clermont Auvergne, INRA, UNH, Unité de Nutrition Humaine, CRNH Auvergne, 63000, Clermont-Ferrand, France 4 Université Clermont Auvergne, CNRS, SIGMA Clermont, Institut Pascal, 63000, ...
gut.bmj4d
Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours
Background—Somatostatin receptor scintigraphy (SRS) and octreotide therapy have both changed the management of gastroenteropancreatic endocrine tumours, but very few data are available on the use of ...
gut.bmj9d
Impairment of spermatogenesis and sperm motility by the high-fat diet-induced dysbiosis of gut microbes
Objective High-fat diet (HFD)-induced metabolic disorders can lead to impaired sperm production. We aim to investigate if HFD-induced gut microbiota dysbiosis can functionally influence ...
gut.bmj13d
Opening the doors of precision medicine: novel tools to assess intestinal barrier in inflammatory bowel disease and colitis-associated neoplasia
Mounting evidence underscores the pivotal role of the intestinal barrier and its convoluted network with diet and intestinal microbiome in the pathogenesis of inflammatory bowel disease (IBD) and ...